Last updated on July 2019

A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma


Brief description of study

A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma

Detailed Study Description

You are being asked to take part in this study because you are experiencing fatigue that is related to your cancer. Cancer related fatigue is a very common symptom in people with cancer.

The purpose of this study is to:
  • See if taking the study agent, armodafinil, at a dose of 150mg or 250mg, will improve problems with fatigue in patients who have been diagnosed with cancer and are experiencing fatigue.
  • See the effects (good and bad) of taking Armodafinil compared to placebo (an inactive agent) on cancer related fatigue.

Clinical Study Identifier: TX143725

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.